Review
doi: 10.2174/0929867013372021.
Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336
Affiliations
- PMID: 11562275
- DOI: 10.2174/0929867013372021
Item in Clipboard
Review
Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336
Curr Med Chem.
2001 Oct.
Abstract
Farnesyl protein transferase (FPT) inhibition is an interesting and promising approach to non-cytotoxic anticancer therapy. Research in this area has resulted in several orally active compounds that are currently in clinical evaluation. This review focuses on FPT inhibitors in clinical trials and concentrates on the benzocycloheptapyridine class, with details on the discovery and development of SCH 66336, currently in Phase II clinical trials.
Similar articles
-
Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.Curr Top Med Chem. 2003;3(10):1103-14. doi: 10.2174/1568026033452104. Curr Top Med Chem. 2003. PMID: 12769711 Review.
-
Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.Anticancer Drugs. 2002 Sep;13(8):891-7. doi: 10.1097/00001813-200209000-00016. Anticancer Drugs. 2002. PMID: 12394276
-
Farnesyl transferase inhibitors as anticancer agents.Eur J Cancer. 2002 Sep;38(13):1685-700. doi: 10.1016/s0959-8049(02)00166-1. Eur J Cancer. 2002. PMID: 12175684 Review.
-
Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.Anticancer Res. 2003 Mar-Apr;23(2A):813-8. Anticancer Res. 2003. PMID: 12820305 Review.
-
Farnesyl transferase inhibitors in the treatment of breast cancer.Expert Opin Investig Drugs. 2003 Mar;12(3):413-21. doi: 10.1517/13543784.12.3.413. Expert Opin Investig Drugs. 2003. PMID: 12605564 Review.
Cited by
-
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.Br J Cancer. 2004 Apr 19;90(8):1508-15. doi: 10.1038/sj.bjc.6601732. Br J Cancer. 2004. PMID: 15083177 Free PMC article. Clinical Trial.
-
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12879-84. doi: 10.1073/pnas.0506001102. Epub 2005 Aug 29. Proc Natl Acad Sci U S A. 2005. PMID: 16129833 Free PMC article.
-
Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas.Mol Cancer. 2008 May 19;7:39. doi: 10.1186/1476-4598-7-39. Mol Cancer. 2008. PMID: 18489761 Free PMC article.
-
Farnesyltransferase inhibitors in myelodysplastic syndrome.Curr Hematol Malig Rep. 2006 Mar;1(1):20-4. doi: 10.1007/s11899-006-0013-8. Curr Hematol Malig Rep. 2006. PMID: 20425327 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
